177 related articles for article (PubMed ID: 9437277)
1. Rate of RhD sensitisation before and after implementation of a community based antenatal prophylaxis programme.
Mayne S; Parker JH; Harden TA; Dodds SD; Beale JA
BMJ; 1997 Dec; 315(7122):1588. PubMed ID: 9437277
[No Abstract] [Full Text] [Related]
2. [Antenatal anti-Rh(D) antigen prophylaxis of Rh/-/- pregnancy in women on first consultation at the St. Sofia Obstetrics-Gynecology Hospital -- Sofia].
Katsulov A; Iankov M; Zlateva K; Blagova A; Gogova K; Savova S
Akush Ginekol (Sofiia); 2001; 40 Suppl 5():7-8. PubMed ID: 11785356
[No Abstract] [Full Text] [Related]
3. [Antenatal anti-Rh(D) antigen prophylaxis].
Katsulov A;
Akush Ginekol (Sofiia); 2001; 40 Suppl 5():3-7. PubMed ID: 11785354
[No Abstract] [Full Text] [Related]
4. Recommendations for the use of anti-D immunoglobulin for Rh prophylaxis. British Blood Transfusion Society and the Royal College of Obstetricians and Gynaecologists.
Lee D; Contreras M; Robson SC; Rodeck CH; Whittle MJ
Transfus Med; 1999 Mar; 9(1):93-7. PubMed ID: 10216910
[No Abstract] [Full Text] [Related]
5. Anti-D immunoglobulin in RhD prophylaxis.
Robson SC; Lee D; Urbaniak S
Br J Obstet Gynaecol; 1998 Feb; 105(2):129-34. PubMed ID: 9501773
[No Abstract] [Full Text] [Related]
6. [Hemolytic disease of the newborn has not vanished from Finland--routine protection of RhD negative mothers during pregnancy is justifiable].
Sainio S; Kuosmanen M
Duodecim; 2012; 128(2):151-7. PubMed ID: 22372070
[TBL] [Abstract][Full Text] [Related]
7. Preventing RhD haemolytic disease of the newborn. Revised guidelines advocate two doses of anti-D immunoglobulin for antenatal prophylaxis.
Lee D
BMJ; 1998 May; 316(7144):1611. PubMed ID: 9596614
[No Abstract] [Full Text] [Related]
8. RhD isoimmunization and current management modalities.
Neal JL
J Obstet Gynecol Neonatal Nurs; 2001; 30(6):589-606. PubMed ID: 11724195
[TBL] [Abstract][Full Text] [Related]
9. Time points and risk factors for RhD immunizations after the implementation of targeted routine antenatal anti-D prophylaxis: A retrospective nationwide cohort study.
Jernman R; Isaksson C; Haimila K; Kuosmanen M; Mäkikallio-Anttila K; Toivonen S; Ordén MR; Sulin K; Tihtonen K; Vääräsmäki M; Sainio S
Acta Obstet Gynecol Scand; 2021 Oct; 100(10):1868-1875. PubMed ID: 34157128
[TBL] [Abstract][Full Text] [Related]
10. Preventing RhD haemolytic disease of the newborn. Services should be centralised for pregnancies affected by RhD haemolytic disease.
Craig JS; McClure BG; Tubman TR
BMJ; 1998 May; 316(7144):1611. PubMed ID: 9616034
[No Abstract] [Full Text] [Related]
11. Appropriate provision of anti-D prophylaxis to RhD negative pregnant women: a scoping review.
Fyfe TM; Ritchey MJ; Taruc C; Crompton D; Galliford B; Perrin R
BMC Pregnancy Childbirth; 2014 Dec; 14():411. PubMed ID: 25491600
[TBL] [Abstract][Full Text] [Related]
12. Routine antenatal Rhesus D immunoglobulin prophylaxis: the results of a prospective 10 year study.
MacKenzie IZ; Bowell P; Gregory H; Pratt G; Guest C; Entwistle CC
Br J Obstet Gynaecol; 1999 May; 106(5):492-7. PubMed ID: 10430201
[TBL] [Abstract][Full Text] [Related]
13. Preventing RhD haemolytic disease of the newborn.
van Dijk B
BMJ; 1997 Dec; 315(7121):1480-1. PubMed ID: 9420481
[No Abstract] [Full Text] [Related]
14. High-throughput, non-invasive prenatal testing for fetal Rhesus D genotype to guide antenatal prophylaxis with anti-D immunoglobulin: a cost-effectiveness analysis.
Saramago P; Yang H; Llewellyn A; Palmer S; Simmonds M; Griffin S
BJOG; 2018 Oct; 125(11):1414-1422. PubMed ID: 29415334
[TBL] [Abstract][Full Text] [Related]
15. Consequences of being Rhesus D immunized during pregnancy and how to optimize new prevention strategies.
Tiblad E; Westgren M; Pasupathy D; Karlsson A; Wikman AT
Acta Obstet Gynecol Scand; 2013 Sep; 92(9):1079-85. PubMed ID: 23750781
[TBL] [Abstract][Full Text] [Related]
16. Economics of antenatal prophylaxis.
Cairns JA
Br J Obstet Gynaecol; 1998 Nov; 105 Suppl 18():19-22. PubMed ID: 9863974
[No Abstract] [Full Text] [Related]
17. Guidelines for antenatal anti-D prophylaxis.
Mason G; Glanville T
Lancet; 2002 Sep; 360(9336):880. PubMed ID: 12243957
[No Abstract] [Full Text] [Related]
18. Cost-effectiveness of first trimester non-invasive fetal RHD screening for targeted antenatal anti-D prophylaxis in RhD-negative pregnant women: a model-based analysis.
Neovius M; Tiblad E; Westgren M; Kublickas M; Neovius K; Wikman A
BJOG; 2016 Jul; 123(8):1337-46. PubMed ID: 26663771
[TBL] [Abstract][Full Text] [Related]
19. Costs and benefits of non-invasive fetal RhD determination.
Teitelbaum L; Metcalfe A; Clarke G; Parboosingh JS; Wilson RD; Johnson JM
Ultrasound Obstet Gynecol; 2015 Jan; 45(1):84-8. PubMed ID: 25380024
[TBL] [Abstract][Full Text] [Related]
20. An audit of the investigation and use of anti-D immunoglobulin prophylaxis in Tayside.
Rennie I; Smith A; Smith R; Rawlinson PS; Clark P
Health Bull (Edinb); 2001 May; 59(3):150-4. PubMed ID: 12664753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
